The study showed a statistically significant 35% placebo-adjusted reduction in pulmonary vascular resistance (PVR). How clinically meaningful is this change for a PAH patient population, and what does it suggest about TPIP’s hemodynamic impact?

An improvement of 35.5 meters in six-minute walk distance (6MWD) was observed versus placebo. How do you interpret this in light of current therapeutic benchmarks, and how might this affect patients’ daily function or prognosis?

A 60% reduction in NT-proBNP levels was reported for TPIP-treated patients. Given its use as a biomarker for cardiac strain, how confident can we be in translating this into long-term cardiovascular benefit?

TPIP’s once-daily dosing and sustained efficacy over a 24-hour window are emphasized in the trial. In your experience, how might this simplify disease management and improve adherence compared to other prostanoids?

75% of patients titrated successfully to the highest dose (640 µg). What does this level of up-titration suggest about TPIP’s tolerability profile, and how does it compare with more traditional prostanoid formulations?

While most TEAEs were mild and expected for prostanoids—cough, headache, flushing—how would you assess the overall safety profile of TPIP in contrast to inhaled treprostinil or IV options?

“Given these encouraging Phase 2b results, what considerations should be prioritized when designing the Phase 3 trials—particularly in terms of endpoints, patient selection, or dosing strategy?

If TPIP proves successful in Phase 3, where do you envision it fitting within the PAH treatment algorithm—alongside oral agents, replacing existing inhaled options, or even as a preferred early intervention?